We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery
BusinessNews

FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery

BarbaraDuck
BarbaraDuck
Share
0 Min Read
SHARE

Basal cell carcinoma is rarely fatal and in many cases surgery is the cure but in some patients is can spread beyond the skin area in to other areas of the body and this is where the new oral drug comes in to help fight and shrink tumors.  image

When the cancer has metastasized, this is about the only option available.  There are a few side effects like loss of hair and food tasting different but the benefits seem to certainly outweigh. The pill is taken once a day and the cost will be around $7k a month.  I do hope insurers start to cover this as it has been an issue in California with covering oral cancer medications.  BD

California Legislature Urging Health Insurance Companies to Cover Chemotherapy–Especially With Breast Cancer Treatments

 

The Food and Drug Administration has for the first time approved a drug to treat advanced cases of the most common skin cancer, basal cell carcinoma, the agency announced Monday.

The drug, a capsule called Erivedge (generically known as vismodegib), treats basal cell carcinoma that has metastasized (spread through the body), or that cannot be treated with surgery.

In a clinical study in 96 people, 30 percent of those with locally advanced basal cell carcinoma (which had spread to surrounding tissue), and 43 percent of those with metastatic cancer (which had spread to distant sites in the body) saw their tumors shrink or heal while taking the drug, according to a statement from the FDA. Patients took one pill by mouth each day. 

Doctors treat non-metastatic cases with surgery, radiation or topical treatments, and have an extremely high success rate. But no other treatments exist for inoperable cases, such as people with tumors that have extended into the brain, or people who would become disfigured from surgery

Basal cell carcinoma is linked to mutations in genes that are part of a signaling pathway called the hedgehog pathway. Erivedge works by inhibiting the hedgehog pathway.

http://vitals.msnbc.msn.com/_news/2012/01/31/10280479-fda-approves-first-drug-for-inoperable-skin-cancer

More Read

Cue the Confetti! Startups Can Begin Soliciting Investors on Monday
Culture Change Is Here: People Are Price-Shopping for Health Care
Dramatic Early Clinical Trial Success for New Cancer Treatment
Will “Medicare As We Know It” Persist, or Will It Change?
California Insurers Slash Number of Doctors You Can See

 

TAGGED:basal cell carcinomaErivedgeFDAskin cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026
Flat editorial illustration: The article connects routine occupational health screening with early exposure detection and better
What Routine Workplace Health Monitoring in Medical Environments Actually Prevents
Uncategorized
November 6, 2026
Flat editorial illustration: The article contrasts structured prelicensure education with ongoing, practice-focused development f
Academic vs. Clinical Education: How Teaching Settings Shape Nursing Learners and Outcomes
Uncategorized
November 6, 2026
Flat editorial illustration: Health-editorial illustration of the two-way relationship between substance use and disrupted sleep,
How Sleep Disruption Feeds the Addiction Cycle and What You Can Do About It
Addiction Recovery Mental Health Wellness
November 6, 2026

You Might also Like

BusinessPublic Health

Why Our HealthCare Spending Doesn’t Make Sense

March 24, 2012
Image
NewsWellness

Person-Centered HealthCare: Living Well

July 5, 2013
BusinessGlobal Healthcare

How Western Companies Can Capitalize on the Opportunities in India

December 23, 2011

Rising Health Costs Affect Us All

March 12, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?